Calliditas Therapeutics AB (CALT) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:CALT • US13124Q1067

40.0001 USD
-0.16 (-0.4%)
Last: Sep 20, 2024, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

CALT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. CALT may be in some trouble as it scores bad on both profitability and health. CALT is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CALT had negative earnings in the past year.
  • In the past year CALT has reported a negative cash flow from operations.
  • In the past 5 years CALT always reported negative net income.
  • In the past 5 years CALT always reported negative operating cash flow.
CALT Yearly Net Income VS EBIT VS OCF VS FCFCALT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M -400M -500M

1.2 Ratios

  • CALT has a Return On Assets (-27.49%) which is in line with its industry peers.
  • Looking at the Return On Equity, with a value of -449.82%, CALT is doing worse than 80.00% of the companies in the same industry.
Industry RankSector Rank
ROA -27.49%
ROE -449.82%
ROIC N/A
ROA(3y)-26.82%
ROA(5y)-22.62%
ROE(3y)-80.89%
ROE(5y)-56.52%
ROIC(3y)N/A
ROIC(5y)N/A
CALT Yearly ROA, ROE, ROICCALT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400

1.3 Margins

  • CALT's Gross Margin of 93.46% is amongst the best of the industry. CALT outperforms 96.41% of its industry peers.
  • CALT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CALT Yearly Profit, Operating, Gross MarginsCALT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • CALT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CALT has about the same amount of shares outstanding.
  • The debt/assets ratio for CALT is higher compared to a year ago.
CALT Yearly Shares OutstandingCALT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
CALT Yearly Total Debt VS Total AssetsCALT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

  • CALT has a Debt/Equity ratio of 9.44. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 9.44, CALT is not doing good in the industry: 84.62% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 9.44
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC6.73%
CALT Yearly LT Debt VS Equity VS FCFCALT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 500M 1B

2.3 Liquidity

  • CALT has a Current Ratio of 2.69. This indicates that CALT is financially healthy and has no problem in meeting its short term obligations.
  • CALT has a Current ratio (2.69) which is in line with its industry peers.
  • A Quick Ratio of 2.59 indicates that CALT has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.59, CALT is in line with its industry, outperforming 48.72% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.69
Quick Ratio 2.59
CALT Yearly Current Assets VS Current LiabilitesCALT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • CALT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -64.52%.
  • CALT shows a strong growth in Revenue. In the last year, the Revenue has grown by 39.27%.
  • The Revenue has been growing by 1013.57% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-64.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.54%
Revenue 1Y (TTM)39.27%
Revenue growth 3Y1013.57%
Revenue growth 5YN/A
Sales Q2Q%107.8%

3.2 Future

  • Based on estimates for the next years, CALT will show a very strong growth in Earnings Per Share. The EPS will grow by 78.56% on average per year.
  • Based on estimates for the next years, CALT will show a very strong growth in Revenue. The Revenue will grow by 39.98% on average per year.
EPS Next Y127%
EPS Next 2Y105.23%
EPS Next 3Y87.75%
EPS Next 5Y78.56%
Revenue Next Year70.05%
Revenue Next 2Y66.46%
Revenue Next 3Y58.16%
Revenue Next 5Y39.98%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
CALT Yearly Revenue VS EstimatesCALT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B
CALT Yearly EPS VS EstimatesCALT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 50 100 150 200 250

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CALT. In the last year negative earnings were reported.
  • CALT is valuated reasonably with a Price/Forward Earnings ratio of 10.59.
  • Based on the Price/Forward Earnings ratio, CALT is valued cheaply inside the industry as 87.69% of the companies are valued more expensively.
  • CALT is valuated cheaply when we compare the Price/Forward Earnings ratio to 27.86, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 10.59
CALT Price Earnings VS Forward Price EarningsCALT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CALT Per share dataCALT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • CALT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as CALT's earnings are expected to grow with 87.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y105.23%
EPS Next 3Y87.75%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CALT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

Calliditas Therapeutics AB

NASDAQ:CALT (9/20/2024, 8:00:02 PM)

40.0001

-0.16 (-0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13
Earnings (Next)11-11
Inst Owners0.08%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.08B
Revenue(TTM)1.60B
Net Income(TTM)-480.36M
Analysts81.54
Price Target45.37 (13.42%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-176.69%
Min EPS beat(2)-181.66%
Max EPS beat(2)-171.73%
EPS beat(4)1
Avg EPS beat(4)-312.91%
Min EPS beat(4)-979.13%
Max EPS beat(4)80.89%
EPS beat(8)4
Avg EPS beat(8)-142.18%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.01%
Min Revenue beat(2)-22.04%
Max Revenue beat(2)22.03%
Revenue beat(4)2
Avg Revenue beat(4)0.57%
Min Revenue beat(4)-22.04%
Max Revenue beat(4)23.96%
Revenue beat(8)4
Avg Revenue beat(8)20.74%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.89%
PT rev (3m)6.52%
EPS NQ rev (1m)-0.67%
EPS NQ rev (3m)61.18%
EPS NY rev (1m)-0.67%
EPS NY rev (3m)-20.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.1%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 10.59
P/S 6.82
P/FCF N/A
P/OCF N/A
P/B 102.24
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.76
EYN/A
EPS(NY)3.78
Fwd EY9.44%
FCF(TTM)-0.9
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS5.87
BVpS0.39
TBVpS-1.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -27.49%
ROE -449.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.46%
FCFM N/A
ROA(3y)-26.82%
ROA(5y)-22.62%
ROE(3y)-80.89%
ROE(5y)-56.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity 9.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.69
Quick Ratio 2.59
Altman-Z N/A
F-Score2
WACC6.73%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)3.75%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-64.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.54%
EPS Next Y127%
EPS Next 2Y105.23%
EPS Next 3Y87.75%
EPS Next 5Y78.56%
Revenue 1Y (TTM)39.27%
Revenue growth 3Y1013.57%
Revenue growth 5YN/A
Sales Q2Q%107.8%
Revenue Next Year70.05%
Revenue Next 2Y66.46%
Revenue Next 3Y58.16%
Revenue Next 5Y39.98%
EBIT growth 1Y-36.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year125.93%
EBIT Next 3Y83.96%
EBIT Next 5Y69.01%
FCF growth 1Y59.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.92%
OCF growth 3YN/A
OCF growth 5YN/A

Calliditas Therapeutics AB / CALT FAQ

What is the fundamental rating for CALT stock?

ChartMill assigns a fundamental rating of 3 / 10 to CALT.


What is the valuation status of Calliditas Therapeutics AB (CALT) stock?

ChartMill assigns a valuation rating of 4 / 10 to Calliditas Therapeutics AB (CALT). This can be considered as Fairly Valued.


How profitable is Calliditas Therapeutics AB (CALT) stock?

Calliditas Therapeutics AB (CALT) has a profitability rating of 1 / 10.